Skip to main content

DNAPrint Acquires Ellipsis Biotherapeutics in All-Stock Deal

NEW YORK, Nov. 15 (GenomeWeb News) - DNAPrint Genomics said today that it will acquire the core clinical genomics and genotyping assets of Ellipsis Biotherapeutics in an all-stock transaction.


Under the terms of the agreement, Ellipsis will sell its core assets in exchange for 6,500,000 shares of DNAPrint Genomics' common stock. Based on DNAPrint's share price today, the deal would be worth approximately $112,000. The transaction is expected to be completed by Nov. 30.


DNAPrint said it will retain Ellipsis' employees and business operations, and will retain the Ellipsis Biotherapeutics name as a subsidiary.


This is the fourth major acquisition that DNAPrint has made in the past six months. In June, the company acquired Trace Genetics in an all-stock deal; in July, the firm bought 18 percent of BioFrontera for approximately $1.8 million; and earlier this month DNAPrint purchased Kenna Technologies in another all-stock deal.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.